Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 7:11:673100.
doi: 10.3389/fcimb.2021.673100. eCollection 2021.

Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies

Dramane Diallo  1 , Anou M Somboro  1   2 , Seydou Diabate  1 , Bacar Baya  1 , Amadou Kone  1 , Yeya S Sarro  1 , Bourahima Kone  1 , Bassirou Diarra  1 , Souleymane Diallo  1 , Mahamadou Diakite  1 , Seydou Doumbia  1 , Yacouba Toloba  1 , Robert L Murphy  3 , Mamoudou Maiga  1   3
Affiliations
Review

Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies

Dramane Diallo et al. Front Cell Infect Microbiol. .

Abstract

Tuberculosis (TB) remains a major public health concern with millions of deaths every year. The overlap with HIV infections, long treatment duration, and the emergence of drug resistance are significant obstacles to the control of the disease. Indeed, the standard first-line regimen TB treatment takes at least six months and even longer for the second-line therapy, resulting in relapses, drug resistance and re-infections. Many recent reports have also shown prolonged and significant damage of the gut microbial community (dysbiosis) from anti-TB drugs that can detrimentally persist several months after the cessation of treatment and could lead to the impairment of the immune response, and thus re-infections and drug resistance. A proposed strategy for shortening the treatment duration is thus to apply corrective measures to the dysbiosis for a faster bacterial clearance and a better treatment outcome. In this review, we will study the role of the gut microbiota in both TB infection and treatment, and its potential link with treatment duration. We will also discuss, the new concept of "Host Microbiota Directed-Therapies (HMDT)" as a potential adjunctive strategy to improve the treatment effectiveness, reduce its duration and or prevent relapses. These strategies include the use of probiotics, prebiotics, gut microbiota transfer, and other strategies. Application of this innovative solution could lead to HMDT as an adjunctive tool to shorten TB treatment, which will have enormous public health impacts for the End TB Strategy worldwide.

Keywords: TB treatment; dysbiosis; gut microbiota; host directed-therapies; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
In the mouse model, TB first-line drugs induce a distinct and long lasting dysbiosis. X-axis = weeks of treatment; Y-axis = bacterial diversity; TB = TB infected, HRZ = isoniazid+rifampin+pyrazinamide treated (Namasivayam et al., 2017).
Figure 2
Figure 2
Our proposed involvement of the microbiota in TB infection and possible microbiota-targeted-adjuvants during tuberculosis treatment.
See this image and copyright information in PMC

References

    1. Adithya K. K., Rajeev R., Selvin J., Seghal Kiran G. (2021). Dietary Influence on the Dynamics of the Human Gut Microbiome: Prospective Implications in Interventional Therapies. ACS Food Sci. Technol. 1, 717–736. doi: 10.1021/acsfoodscitech.0c00075 - DOI
    1. Antony S., de Leon M. P. (2018). Probiotics and Its Relationship With the Cardiovascular System. Probiotics Curr. Knowledge Future Prospects 3, 52–68. doi: 10.5772/intechopen.75077 - DOI
    1. Arbex M. A., Varella M., de C. L., de Siqueira H. R., de Mello F. A. F. (2010). Antituberculosis Drugs: Drug Interactions, Adverse Effects, and Use in Special Situations. Part 1: First-Line Drugs. J. Bras. Pneumol. 36, 626–640. doi: 10.1590/s1806-37132010000500016 - DOI - PubMed
    1. Arnold I. C., Hutchings C., Kondova I., Hey A., Powrie F., Beverley P., et al. . (2015). Helicobacter Hepaticus Infection in BALB/c Mice Abolishes Subunit-Vaccine-Induced Protection Against M. Tuberculosis. Vaccine 33, 1808–1814. doi: 10.1016/j.vaccine.2015.02.041 - DOI - PMC - PubMed
    1. Effect of Liquid Probiotics on the Growth of Mycobacterium Tuberculosis In Vitro. - PubMed

Publication types

Substances